---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-311070"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-20T23:56:59.414360+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma to acquire U.S. rights of FYCOMPA from Eisai for $160M upfront

## Summary
- $160M upfront at closing; potential $25M milestone if patent exclusivity extended to June 2026.
- FYCOMPA U.S. net revenues approx. $136M for Eisai fiscal year ending March 2023.
- Deal expected to be EBITDA and EPS accretive in 2023; all-cash, no financing contingencies.
- Includes exclusive option to evaluate and negotiate acquisition of a rare epilepsy pipeline asset.
- Expected close Q1 2023, subject to customary closing conditions and U.S. regulatory clearances.

## SEC filing metadata
- accession: 0001193125-22-311070
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/0001193125-22-311070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/d432372d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-311070
- JSON: https://secwatch.observer/filing/0001193125-22-311070.json
- Plain text: https://secwatch.observer/filing/0001193125-22-311070.txt

## Key facts
- Material Agreements
  CATALYST PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Eisai Co., Ltd valued at $160 million (effective 2022-12-17).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Eisai Co., Ltd
  - Value: $160 million
  - Effective: 2022-12-17
  source text: On December 17, 2022, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Eisai Co., Ltd (“ Eisai ”), pursuant to which the Company has agreed to acquire from Eisai the U.S. rights for FYCOMPA ® (perampanel) CIII.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/0001193125-22-311070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.